Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors

Status Withdrawn

Clinical Trial Summary

The goal of this study is to apply allogeneic tumor cell vaccination for immunotherapy in patients with micro-metastatic disease and/or in patients at high risk disease progression. The present study will use allogeneic tumor cell lines for tumor cell vaccines that share MHC determinants with the patient aiming to overcome possible restriction of antigen presentation.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label

Related Conditions & MeSH terms

Metastatic Solid Tumors

Clinical Trial Details

NCT number	NCT00148993
Study type	Interventional
Source	Hadassah Medical Organization
Contact
Status	Withdrawn
Phase	Phase 1/Phase 2
Start date	July 1998
Completion date	July 2005

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03993873` - Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET	Phase 1/Phase 2
Recruiting	`NCT05494918` - First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors	Phase 1
Completed	`NCT02281409` - Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors	Phase 1/Phase 2
Completed	`NCT01928459` - Phase 1b Trial of BGJ398/BYL719 in Solid Tumors	Phase 1
Completed	`NCT01449370` - Dose Escalation Study of MLN1117 in Subjects With Advanced Cancer	Phase 1
Recruiting	`NCT06031441` - A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors	Phase 1
Active, not recruiting	`NCT03059823` - A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors	Phase 1
Terminated	`NCT03573544` - This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.	Phase 1/Phase 2
Active, not recruiting	`NCT03893955` - A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors	Phase 1
Completed	`NCT00878423` - Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors	Phase 1
Withdrawn	`NCT00149019` - Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies.	Phase 2
Recruiting	`NCT03093116` - A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements	Phase 1/Phase 2
Terminated	`NCT03854227` - A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors	Phase 1
Recruiting	`NCT04094610` - A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations	Phase 1/Phase 2
Active, not recruiting	`NCT01543763` - Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors	Phase 1
Terminated	`NCT02228811` - A Study of DCC-2701 in Participants With Advanced Solid Tumors	Phase 1
Recruiting	`NCT05853367` - Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)	Phase 1
Completed	`NCT02097810` - Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.	Phase 1
Recruiting	`NCT05836324` - A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors	Phase 1
Completed	`NCT03910530` - A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors	Phase 1